Cancer Research and Treatment

Original Articles

Real-World Effectiveness and Safety of Intravenous Daratumumab in Patients with Multiple Myeloma: A Multicenter, Observational Study from Korea: Youngil Koh, Sung-Soo Yoon, Kihyun Kim, Je-Jung Lee, Sung-Hoon Jung, Sang Eun Yoon, Sung-Soo Park, YoungJu Park, Soomin Yoon, Chang-Ki Min; Received August 14, 2024 Accepted December 22, 2024 Published online December 24, 2024; DOI: https://doi.org/10.4143/crt.2024.781 [Accepted]

Abstract PDF: Purpose
Daratumumab is a novel, first-in-class monoclonal antibody approved for use as monotherapy and in combination with other treatments for patients with multiple myeloma (MM). The aim of this observational study was to evaluate the effectiveness and safety of daratumumab in real-world clinical practice.
Materials and Methods
This observational multicenter study collected data from patients with MM treated in Korea between June 1, 2018, and February 28, 2022.
Results
125 patients with a diagnosis of MM were included and followed until discontinuation or completion of 52 weeks’ follow-up. The median age was 67 years, and 97.6% of patients received more than three prior LOTs. The overall response rate was 52.5% (95% confidence interval [CI], 43.2 to 61.8), and a very good partial response was observed in 19.5% of patients (95% CI, 12.8 to 27.8). Of the patients who achieved a partial or higher response (52.5%), the median time to first response was 2.4 months (95% CI, 1.8 to 3.4), and the median time from start of daratumumab treatment until progressive disease was 4.1 months (95% CI, 2.9 to 5.1). Fever (24.0%) was the most frequently recorded adverse event (AE), while anemia (8.8%) and neutropenia (8.0%) were the most frequently observed grade 3-4 AEs. Overall, no unexpected safety signals were observed.
Conclusion
In a rapidly evolving treatment landscape, this analysis provides insight into the real-world outcomes for patients with MM receiving daratumumab in Korea and reveals that real-world outcomes were improved over results demonstrated in a clinical trial setting.

507 View
63 Download

Hematologic malignancy

Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913): Ho-Jin Shin, Do-Young Kim, Kihyun Kim, Chang-Ki Min, Je-Jung Lee, Yeung-Chul Mun, Won-Sik Lee, Sung-Nam Lim, Jin Seok Kim, Joon Ho Moon, Da Jung Kim, Soo-Mee Bang, Jong-Ho Won, Jae-Cheol Jo, Young Il Koh; Cancer Res Treat. 2024;56(3):956-966. Published online March 4, 2024; DOI: https://doi.org/10.4143/crt.2024.074

Abstract PDF PubReader ePub

Purpose
The role of allogeneic stem cell transplantation (alloSCT) in multiple myeloma (MM) treatment remains controversial. We conducted a retrospective, multicenter, nationwide study in Korea to evaluate the outcomes of alloSCT in Asian patients with MM.
Materials and Methods
Overall, 109 patients with MM who underwent alloSCT between 2003 and 2020 were included in this study. Data were collected from the Korean Multiple Myeloma Working Party Registry.
Results
The overall response rate and stringent complete response plus complete response (CR) rates were 67.0 and 46.8%, respectively, after alloSCT. At a median follow-up of 32.5 months, the 3-year probability of progression-free survival (PFS) and overall survival (OS) rates were 69.3% and 71.8%, respectively. The 3-year probabilities of OS rates in the upfront alloSCT, tandem auto-alloSCT, and later alloSCT groups were 75.0%, 88.9%, and 61.1%, respectively. Patients who achieved CR before or after alloSCT had significantly longer OS (89.8 vs. 18 months and 89.8 vs. 15.2 months, respectively). Even though patients who did not achieve CR prior to alloSCT, those who achieve CR after alloSCT had improved PFS and OS compared to those who had no achievement of CR both prior and after alloSCT. Patients who underwent alloSCT with 1-2 prior treatment lines had improved PFS (22.4 vs. 4.5 months) and OS (45.6 vs. 15.3 months) compared to those with three or more prior treatment lines.
Conclusion
AlloSCT may be a promising therapeutic option especially for younger, chemosensitive patients with earlier implementation from relapse.

Citations

Citations to this article as recorded by

Prognostic factors and treatment outcomes of allogeneic stem cell transplantation in lymphoid malignancy
Hyungsoon Kim, Haerim Chung, Hye Won Kook, Soo-Jeong Kim, Yu Ri Kim, Hyunsoo Cho, June-Won Cheong
Blood Research.2025;[Epub] CrossRef

2,420 View
109 Download
1 Web of Science
1 Crossref

Case Reports

Three Cases of Synchronous Solid Tumor and Multiple Myeloma: Sang Hoon Ji, Joon Oh Park, Jeeyun Lee, Mi Jung Oh, Do Hyoung Lim, Byeong-Bae Park, Keun Woo Park, Se-Hoon Lee, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H Lee, Keunchil Park; Cancer Res Treat. 2004;36(5):338-340. Published online October 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.338

Abstract PDF PubReader ePub

The association between a multiple myeloma and a secondary solid tumor is not well established. Some reports showed an increased risk of secondary solid neoplasms in multiple myeloma patients, but others have not. Three cases of the synchronous occurrence of multiple myelomas and solid tumors, namely, a small cell carcinoma of the lung, an adenocarcinoma of the colon and a squamous carcinoma of the pyriform sinus were experienced at our hospital. Therefore, herein is reported the clinical courses and treatment results. The stage of multiple myeloma was Durie-Salmon stage I in all of three cases; therefore, the solid tumors were treated as a primary target because the prognosis of early stage multiple myeloma is generally better than that of advanced solid tumor, while a smoldering or stage I myeloma do not need primary therapy until progression of the multiple myeloma. Two patients died of their solid tumors, but one patient is alive.

Citations

Citations to this article as recorded by

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
Koki Tamai, Hajime Hirose, Yo Akazawa, Yukihiro Yoshikawa, Masatoshi Nomura, Hiroshi Takeyama, Masahiro Tokunaga, Mitsuyoshi Tei, Shu Okamura, Yusuke Akamaru
Surgical Case Reports.2024;[Epub] CrossRef
The importance of oncological alertness in the differential diagnosis of inflammatory changes in the lungsdetected as a result of differential diagnosis of pneumonia
M. F. Petrukhnova, O. O. Voronkova, O. E. Buyanova, O. N. Antyufeeva, A. E. Kamalova, M. V. Kozhevnikova, I. S. Ilgisonis, Yu. N. Belenkov
Meditsinskiy sovet = Medical Council.2024; (9): 100. CrossRef
Synchronous multiple myeloma and lung adenocarcinoma: A clinical series
Fang Ye, Huan Wang, Ningning Li, Aijun Liu, Wenming Chen
Indian Journal of Pathology and Microbiology.2024; 67(2): 390. CrossRef
Simultaneous multiple myeloma and non‑small cell lung carcinoma: A case report and review of the literature
Huan-Huan Dong, Jing Li, Lin Kang, Qiang Wei, Yan Li
Oncology Letters.2022;[Epub] CrossRef
Rapid progression of gastric cancer with liver metastasis after discontinuation of lenalidomide in a patient with concurrent multiple myeloma: A case report
Naoto Ujiie, Yoshitaka Enomoto, Naruhito Takido, Yasushi Kawaharada, Masashi Zuguchi, Yosuke Kubota
International Journal of Surgery Case Reports.2021; 81: 105834. CrossRef
Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma
Wenli Zuo, Xinghu Zhu, Jingke Yang, Zhenyang Mei, Mei Deng, Quande Lin, Yongping Song, Qingsong Yin
Medicine.2017; 96(1): e5787. CrossRef
Drastic Response to Nivolumab in a Case Demonstrating a Rapid Recurrence of Pulmonary Pleomorphic Carcinoma That Developed After Chemotherapy for Comorbid Myeloma Kidney
Aya Yamamoto, Takashi Iwata, Koji Hashimoto
Haigan.2017; 57(7): 849. CrossRef
Challenges in managing a patient with multiple primary malignancies
Nataliya Mar, David Askin, Jerry George, Colette Spaccavento, Robert Graham, Lynn Ratner
Community Oncology.2012; 9(12): 377. CrossRef
¿Asociación entre colangiocarcinoma y mieloma múltiple?
Laura Gómez-Escolar Viejo, Gema Soler Sala, Vanessa Castaño Giraldo, José María Palazón Azorín, Miguel Pérez-Mateo Regadera
Gastroenterología y Hepatología.2008; 31(6): 402. CrossRef
Synchronous Presentation of Multiple Myeloma and Lung Cancer
Rishu Agarwal, Ritu Gupta, Archana Bhaskar, Atul Sharma, Sanjay Thulkar, Lalit Kumar
Journal of Clinical Oncology.2008; 26(35): 5814. CrossRef

10,310 View
54 Download
10 Crossref

Esophageal Squamous Cell Carcinoma Recurring as a Solitary Renal Mass: Do Hyoung Lim, Young-Hyuck Im, Sang Hoon Ji, Byeong-Bae Park, Mi Jung Oh, Jeeyun Lee, Keun Woo Park, Se-Hoon Lee, Joon-Oh Park, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Won Ki Kang, Mark H Lee, Kwanmien Kim, Young Mog Shim, Keunchil Park; Cancer Res Treat. 2004;36(4):271-274. Published online August 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.4.271

Abstract PDF PubReader ePub

Herein, a case of solitary, unilateral renal metastasis in a patient with curatively resected thoracic esophageal carcinoma, who achieved a pathological complete remission after neoadjuvant concurrent chemoradiotherapy, is reported. The kidney is the 4^th or 5^th most common visceral metastasis site of a primary esophageal carcinoma. More than 50% of renal metastases typically show bilateral involvement. Solitary, unilateral renal metastasis is extremely rare. Renal metastases from a primary esophageal carcinoma are usually latent and its diagnosis is very unusual in a live patient. The solitary renal metastasis in this case was not accompanied by metastases to other sites. The value of a nephrectomy in solitary renal metastasis of esophageal cancer is not known due to the rarity of such cases. A nephrectomy could be justified in limited situations, such as with uncertainty of histological diagnosis, severe life-threatening hematuria, which cannot be controlled by embolization, or solitary renal metastasis with a long disease-free interval.

Citations

Citations to this article as recorded by

Rapidly Rising Serum Creatinine in a Patient With Colorectal Adenocarcinoma and Eosinophilia: A Quiz
Athiphat Banjongjit, Vorachai Ratanatharathorn, Piyanut Mahanupap, Winyou Mitarnun
American Journal of Kidney Diseases.2024; 83(2): A14. CrossRef
Esophageal squamous cell carcinoma metastases to kidney and renal hilar lymph nodes through epithelial-mesenchymal transition: a case report and literature review
Nai-Jun Fan
American Journal of Translational Research.2024; 16(5): 1825. CrossRef
Secondary Tumors of the Kidney: A Comprehensive Clinicopathologic Analysis
Faisal Saeed, Adeboye O. Osunkoya
Advances in Anatomic Pathology.2022; 29(4): 241. CrossRef
Surgery for metachronous oligometastatic esophageal cancer: Is there enough evidence?
Dimitrios Schizas, Michail Vailas, Maria Sotiropoulou, Ioannis A. Ziogas, Konstantinos S. Mylonas, Ioannis Katsaros, Alkistis Kapelouzou, Theodore Liakakos
Cirugía Española.2021; 99(7): 490. CrossRef
Surgery for metachronous oligometastatic esophageal cancer: Is there enough evidence?
Dimitrios Schizas, Michail Vailas, Maria Sotiropoulou, Ioannis A. Ziogas, Konstantinos S. Mylonas, Ioannis Katsaros, Alkistis Kapelouzou, Theodore Liakakos
Cirugía Española (English Edition).2021; 99(7): 490. CrossRef
The role of surgical treatment in isolated organ recurrence of esophageal cancer—a systematic review of the literature
Dimitrios Schizas, Ioannis I. Lazaridis, Demetrios Moris, Aikaterini Mastoraki, Lazaros-Dimitrios Lazaridis, Diamantis I. Tsilimigras, Nikolaos Charalampakis, Theodore Liakakos
World Journal of Surgical Oncology.2018;[Epub] CrossRef
Esophageal Cancer with Solitary Renal Metastasis Treated with Multidisciplinary Therapy: A Case Report and Mini Review of the Literature
Kyoung Sik Nam, Kyoungwon Jung, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Jae Hyun Kim
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2017; 17(1): 39. CrossRef
Esophageal Cancer Metastases to Unexpected Sites: A Systematic Review
Osama Shaheen, Abdulaziz Ghibour, Bayan Alsaid
Gastroenterology Research and Practice.2017; 2017: 1. CrossRef
FDG PET/CT in 2 Cases of Renal Metastasis From Esophageal Squamous Cell Carcinoma
Qian Zhao, Aisheng Dong, Bo Yang, Yang Wang, Changjing Zuo
Clinical Nuclear Medicine.2017; 42(11): 896. CrossRef
Solitary renal metastasis of esophageal squamous cell carcinoma mimicking primary renal neoplasm – A case report and literature review
Kai-Po Chang, Chi-Ping Huang, Han Chang
BioMedicine.2016;[Epub] CrossRef
Unilateral renal metastases after definitive chemoradiation in squamous cell carcinoma of esophagus: A case report and review literature
Kapil Dev, Jaiprakash Gurawalia, Sandeep Nayak, Balu Sadasivan
Asian Journal of Oncology.2016; 02: 046. CrossRef
Renal metastasis after esophagectomy of esophageal squamous cell carcinoma: a case report and literature review
Yan Sun, Xinmin Yu, Yiping Zhang
World Journal of Surgical Oncology.2014;[Epub] CrossRef
Esophageal Adenocarcinoma with Solitary Renal Metastasis
Thomas D. Willson, Matthew J. Blecha, Mark M. Connolly, Francis J. Podbielski
Journal of Gastrointestinal Cancer.2013; 44(3): 351. CrossRef
Synchronous Squamous Cell Carcinomas of the Esophagus and Renal Pelvis
Te-Chun Hsieh, Yu-Chin Wu, Shung-Shung Sun, I-Ping Chiang, Chun-Fan Yang, Kuo-Yang Yen, Chia-Hung Kao
Clinical Nuclear Medicine.2011; 36(11): e171. CrossRef

9,818 View
62 Download
14 Crossref

Use of GCDFP-15 (BRST-2) as a Specific Immunocytochemical Marker for Diagnosis of Gastric Metastasis of Breast Carcinoma: Keon Woo Park, Young Hyuck Im, Jeeyun Lee, Eungho Kim, Hyuk Lee, Bong Geun Song, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Won Ki Kang, Mark H Lee, Keunchil Park; Cancer Res Treat. 2003;35(5):460-464. Published online October 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.5.460

Abstract PDF

Metastasis of breast cancer to the stomach is relatively uncommon and typically occurs in patients with disseminated diseases. This may cause difficulty in differentiating it from primary gastric carcinoma. The correct diagnosis of the primary source is important, since the treatment and prognosis of metastatic breast cancer is quite different from those of metastatic gastric cancer. Immunohistochemical staining with GCDFP-15 (gross cystic disease fluid protein-15) can be used to differentiate primary gastric carcinoma and gastric metastasis from breast cancer. We report two cases of gastric metastasis of breast cancer by describing their clinical course, illustrating the histologic findings, and showing the results of immunohistochemical staining with GCDFP-15.

Citations

Citations to this article as recorded by

Gastrointestinal metastasis of breast cancer: Exploring the path ahead
Peng-Yue Zhao, Zhen-Ting Zhao, Song-Yan Li, Fiona Simpson, Xiao-Hui Du
Medicine Plus.2024; 1(4): 100055. CrossRef
Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer
Natalia Sauer, Igor Matkowski, Grażyna Bodalska, Marek Murawski, Piotr Dzięgiel, Jacek Calik
Cells.2023; 12(18): 2252. CrossRef
Gastric Metastasis from Breast Cancer
So Yoon Yoon, Ki-Nam Shim
The Korean Journal of Gastroenterology.2013; 61(1): 54. CrossRef
Colon Obstruction due to Colonic Metastasis of a Breast Carcinoma
Do Hyoung Kim, In Kyu Lee, Chang Hyun Oh, Yoon Suk Lee, Jong Kyung Park, Woo Chan Park, Hae Myung Jeon, Jae Ho Byun, Gyeoung-Sin Park, Suk Kyun Chang
Journal of the Korean Society of Coloproctology.2008; 24(2): 144. CrossRef

3,912 View
30 Download
4 Crossref

Original Article

Hematologic malignancy

Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study: Jongheon Jung, Kihyun Kim, Sung-Hoon Jung, Sung-Soo Yoon, Jae Hoon Lee, Jin Seok Kim, Ho-Jin Shin, Soo-Mee Bang, Sang Kyun Sohn, Cheolwon Suh, Dok Hyun Yoon, Sun-Young Kong, Chang-Ki Min, Hyeon-Seok Eom, The Korean Multiple Myeloma Working Party; Cancer Res Treat. 2023;55(2):693-703.; DOI: https://doi.org/10.4143/crt.2022.952

Abstract PDF Supplementary Material PubReader ePub

Purpose
A three-drug combination of cyclophosphamide, bortezomib, and dexamethasone (CVD) shows significant efficacy and manageable toxicity as induction therapy in patients with multiple myeloma.
Materials and Methods
In this phase II study, we enrolled 45 patients who achieved a very good partial response (VGPR) or partial response (PR) after autologous stem cell transplantation (ASCT) and evaluated the efficacy and toxicity of CVD consolidation. CVD consolidation comprised three cycles of cyclophosphamide 300 mg/m² orally on days 1, 8, and 15, and bortezomib 1.3 mg/m² subcutaneously on days 1, 8, 15, and 22, along with dexamethasone 20 mg orally or intravenously on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23.
Results
At enrollment, 39 patients (86.7%) showed VGPR, and nine (13.3%) presented with PR. Nineteen patients (45.2%) achieved a complete response or better as their best response after the end of consolidation. Overall, 22 of 42 patients (52.4%) experienced an improved response status with CVD consolidation. Three-year overall survival and progression-free survival rates were 89.0% and 42.7%, respectively. The most common non-hematologic toxicities were peripheral neuropathy and infection (20.5%), with no grade ≥ 3 neuropathy observed.
Conclusion
These results showed that CVD consolidation therapy improved the response with reasonable toxicity in patients with residual disease after ASCT. This trial was registered with the Clinical Research Information Service, Republic of Korea (KCT0001327).

Citations

Citations to this article as recorded by

Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
Morie A. Gertz
Hematology/Oncology Clinics of North America.2024; 38(2): 407. CrossRef
Ginsenoside Rg1 inhibits multiple myeloma and overcomes bortezomib resistance through AMPK-mTOR pathway
Li Lin, Dong Chen, Shuangyue Li, Tiantian Wang
Heliyon.2024; 10(13): e33935. CrossRef

5,818 View
167 Download
2 Web of Science
2 Crossref

First
Prev
Page of 1
Next
Last

Search